Today, we welcome Dr Rosanne Dunn, Chief Scientific Officer and co-founder of <a href='https://haemalogix.com'>HaemaLogiX</a>, an Australian clinical-stage biotech company that&apos;s developing next-generation immunotherapies for multiple myeloma and other plasma cell disorders.HaemaLogiX is taking a precision approach by targeting novel antigens that are expressed exclusively on malignant plasma cells, sparing healthy ones. Recent peer-reviewed research has validated KMA and LMA as high-value targets, reinforcing the company&apos;s unique positioning in the field.Rosanne shares her journey from antibody engineering to building HaemaLogiX, the science behind their differentiated targets, the latest clinical and preclinical progress, and her perspectives on the future of immunotherapy for blood cancers as the company gears up for key milestones, including a planned IPO later this year.<ul><li>01:15 Meet Rosanne Dunn</li><li>07:52 HaemalogiX&apos;s mission and novel antigens</li><li>09:53 Overview of multiple myeloma and its symptoms</li><li>12:19 Targeting malignant plasma cells while sparing normal ones</li><li>19:25 Recent Peer-Reviewed Research</li><li>26:08 Synergy with IMiDs like Revlimid</li><li>29:08 Potential patient impact and quality of life</li><li>35:05 Planned IPO in 2026 and funding needs</li></ul>Interested in being a sponsor of an episode of our podcast? <a href='https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&amp;utm_medium=podcast_description&amp;utm_source=podcast'>Discover how you can get involved here!</a> Stay updated by <a href='https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&amp;utm_medium=podcast_description&amp;utm_source=podcast'>subscribing to our newsletter</a>To dive deeper into the topic: <ul><li><a href='https://www.labiotech.eu/best-biotech/cancers-immunotherapy-cure/'>5 cancers that immunotherapy can cure</a></li><li><a href='https://www.labiotech.eu/trends-news/bio-europe-partnering-australian-biotech-lessons/'>BIO-Europe partnering: Australian biotech companies share their experiences</a></li><li><a href='https://www.labiotech.eu/in-depth/rd-tax-incentive-biotech-boost-australia/'>How are R&amp;D Tax Incentives shaping Australia’s biotech future?</a></li></ul>

<description>&lt;p&gt;Today, we welcome Dr Rosanne Dunn, Chief Scientific Officer and co-founder of &lt;a href='https://haemalogix.com'&gt;HaemaLogiX&lt;/a&gt;, an Australian clinical-stage biotech company that&amp;apos;s developing next-generation immunotherapies for multiple myeloma and other plasma cell disorders.&lt;/p&gt;&lt;p&gt;HaemaLogiX is taking a precision approach by targeting novel antigens that are expressed exclusively on malignant plasma cells, sparing healthy ones. Recent peer-reviewed research has validated KMA and LMA as high-value targets, reinforcing the company&amp;apos;s unique positioning in the field.&lt;/p&gt;&lt;p&gt;Rosanne shares her journey from antibody engineering to building HaemaLogiX, the science behind their differentiated targets, the latest clinical and preclinical progress, and her perspectives on the future of immunotherapy for blood cancers as the company gears up for key milestones, including a planned IPO later this year.&lt;/p&gt;&lt;ul&gt;&lt;li&gt;&lt;b&gt;01:15&lt;/b&gt; Meet Rosanne Dunn&lt;/li&gt;&lt;li&gt;&lt;b&gt;07:52&lt;/b&gt; HaemalogiX&amp;apos;s mission and novel antigens&lt;/li&gt;&lt;li&gt;&lt;b&gt;09:53&lt;/b&gt; Overview of multiple myeloma and its symptoms&lt;/li&gt;&lt;li&gt;&lt;b&gt;12:19&lt;/b&gt; Targeting malignant plasma cells while sparing normal ones&lt;/li&gt;&lt;li&gt;&lt;b&gt;19:25&lt;/b&gt; Recent Peer-Reviewed Research&lt;/li&gt;&lt;li&gt;&lt;b&gt;26:08&lt;/b&gt; Synergy with IMiDs like Revlimid&lt;/li&gt;&lt;li&gt;&lt;b&gt;29:08&lt;/b&gt; Potential patient impact and quality of life&lt;/li&gt;&lt;li&gt;&lt;b&gt;35:05&lt;/b&gt; Planned IPO in 2026 and funding needs&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;Interested in being a sponsor of an episode of our podcast? &lt;a href='https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&amp;amp;utm_medium=podcast_description&amp;amp;utm_source=podcast'&gt;Discover how you can get involved here!&lt;/a&gt; &lt;/p&gt;&lt;p&gt;Stay updated by &lt;a href='https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&amp;amp;utm_medium=podcast_description&amp;amp;utm_source=podcast'&gt;subscribing to our newsletter&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;To dive deeper into the topic: &lt;/b&gt;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/best-biotech/cancers-immunotherapy-cure/'&gt;5 cancers that immunotherapy can cure&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/trends-news/bio-europe-partnering-australian-biotech-lessons/'&gt;BIO-Europe partnering: Australian biotech companies share their experiences&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/in-depth/rd-tax-incentive-biotech-boost-australia/'&gt;How are R&amp;amp;D Tax Incentives shaping Australia’s biotech future?&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;</description>

Today, we welcome Dr Rosanne Dunn, Chief Scientific Officer and co-founder of HaemaLogiX, an Australian clinical-stage biotech company that's developing next-generation immunotherapies for multiple myeloma and other plasma cell disorders. HaemaLogiX is taking a precision approach by targeting novel antigens that are expressed exclusively on malignant plasma cells, sparing healthy ones. Recent peer-reviewed research has validated KMA and LMA as high-value targets, reinforcing the company's uni...

HaemaLogiX - precision immunotherapy for multiple myeloma

Today we welcome Koenraad Wiedhaup, Co-Founder and CEO of <a href='https://leydenlabs.com'>Leyden Labs</a>, and Clarissa Koch, the company&apos;s Chief Scientific Officer.Leyden Labs is pioneering a revolutionary non-vaccine approach to combat respiratory viruses like influenza and coronaviruses. Recently, they <a href='https://www.science.org/doi/10.1126/scitranslmed.adz1580'>published groundbreaking data in Science Translational Medicine</a>, demonstrating that their intranasal antibody spray is safe, well-tolerated, and delivers sustained protection right at the virus&apos;s entry point: the nose. This innovation addresses the shortcomings of traditional flu vaccines, which average just 13% effectiveness against infection and provide even less for vulnerable groups like the elderly and immunocompromised.We&apos;ll dive into the science, the company&apos;s journey since its 2020 founding, and their recent €50 million European funding boost amid U.S. biotech challenges.01:33: Meet Koenraad Wiedhaup03:13: Meet Clarissa Koch04:16: Leyden Labs&apos; origin story06:21: Mucosal protection platform explained08:57: Complementing existing vaccines11:47: Science of mucosal immunity13:24: PanFlu lead candidate overview16:42: Key findings from recent publication22:02: Funding and future preparednessInterested in being a sponsor of an episode of our podcast? <a href='https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&amp;utm_medium=podcast_description&amp;utm_source=podcast'>Discover how you can get involved here!</a> Stay updated by <a href='https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&amp;utm_medium=podcast_description&amp;utm_source=podcast'>subscribing to our newsletter</a>To dive deeper into the topic: <ul><li><a href='https://www.labiotech.eu/best-biotech/biotech-companies-the-netherlands/'>Seven biotech companies to know in the Netherlands</a></li><li><a href='https://www.labiotech.eu/in-depth/the-netherlands-biotech-hub/'>The Netherlands’ biotech scene: The country sets its sights on becoming a global leader by 2040 </a></li><li><a href='https://www.labiotech.eu/trends-news/influenza-deals-surge/'>Influenza solution deals pile up as pandemic preparedness increases</a> </li></ul>

<description>&lt;p&gt;Today we welcome Koenraad Wiedhaup, Co-Founder and CEO of &lt;a href='https://leydenlabs.com'&gt;Leyden Labs&lt;/a&gt;, and Clarissa Koch, the company&amp;apos;s Chief Scientific Officer.&lt;/p&gt;&lt;p&gt;Leyden Labs is pioneering a revolutionary non-vaccine approach to combat respiratory viruses like influenza and coronaviruses. Recently, they &lt;a href='https://www.science.org/doi/10.1126/scitranslmed.adz1580'&gt;published groundbreaking data in Science Translational Medicine&lt;/a&gt;, demonstrating that their intranasal antibody spray is safe, well-tolerated, and delivers sustained protection right at the virus&amp;apos;s entry point: the nose. This innovation addresses the shortcomings of traditional flu vaccines, which average just 13% effectiveness against infection and provide even less for vulnerable groups like the elderly and immunocompromised.&lt;/p&gt;&lt;p&gt;We&amp;apos;ll dive into the science, the company&amp;apos;s journey since its 2020 founding, and their recent €50 million European funding boost amid U.S. biotech challenges.&lt;/p&gt;&lt;p&gt;01:33: Meet Koenraad Wiedhaup&lt;/p&gt;&lt;p&gt;03:13: Meet Clarissa Koch&lt;/p&gt;&lt;p&gt;04:16: Leyden Labs&amp;apos; origin story&lt;/p&gt;&lt;p&gt;06:21: Mucosal protection platform explained&lt;/p&gt;&lt;p&gt;08:57: Complementing existing vaccines&lt;/p&gt;&lt;p&gt;11:47: Science of mucosal immunity&lt;/p&gt;&lt;p&gt;13:24: PanFlu lead candidate overview&lt;/p&gt;&lt;p&gt;16:42: Key findings from recent publication&lt;/p&gt;&lt;p&gt;22:02: Funding and future preparedness&lt;/p&gt;&lt;p&gt;Interested in being a sponsor of an episode of our podcast? &lt;a href='https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&amp;amp;utm_medium=podcast_description&amp;amp;utm_source=podcast'&gt;Discover how you can get involved here!&lt;/a&gt; &lt;/p&gt;&lt;p&gt;Stay updated by &lt;a href='https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&amp;amp;utm_medium=podcast_description&amp;amp;utm_source=podcast'&gt;subscribing to our newsletter&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;To dive deeper into the topic: &lt;/b&gt;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/best-biotech/biotech-companies-the-netherlands/'&gt;Seven biotech companies to know in the Netherlands&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/in-depth/the-netherlands-biotech-hub/'&gt;The Netherlands’ biotech scene: The country sets its sights on becoming a global leader by 2040 &lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/trends-news/influenza-deals-surge/'&gt;Influenza solution deals pile up as pandemic preparedness increases&lt;/a&gt; &lt;/li&gt;&lt;/ul&gt;</description>

Today we welcome Koenraad Wiedhaup, Co-Founder and CEO of Leyden Labs, and Clarissa Koch, the company's Chief Scientific Officer. Leyden Labs is pioneering a revolutionary non-vaccine approach to combat respiratory viruses like influenza and coronaviruses. Recently, they published groundbreaking data in Science Translational Medicine, demonstrating that their intranasal antibody spray is safe, well-tolerated, and delivers sustained protection right at the virus's entry point: the nose. This i...

How Leyden Labs is revolutionizing flu protection with its intranasal antibody spray

Today, we welcome Janita Good, a Partner at <a href='https://www.fieldfisher.com/en/sectors/life-sciences'>Fieldfisher</a> with nearly two decades of experience advising top organizations in pharmaceuticals, biotechnology, and medical devices. With a D.Phil. in Biochemistry from the University of Oxford, Janita brings a unique blend of scientific insight and legal expertise to her work on venture investments, joint ventures, partnerships, and M&amp;A deals. She&apos;s advised on landmark transactions, including funding rounds for Phynova and MedAnnex, and collaborations like Intelligent Ultrasound&apos;s AI imaging partnerships.In this episode, Janita shares practical guidance for biotech leaders on timing partnerships with larger pharma companies, planning for commercialization from the start, balancing optimistic fundraising with realistic deal projections, and avoiding common legal pitfalls in M&amp;A. We&apos;ll also look ahead to emerging trends in the sector and talk through the best way to structure a company for tax effective partnering and licensing.01:29: Meet Janita Good04:42: Fieldfisher&apos;s life sciences focus07:20: Fieldfisher’s differentiated approach09:41: Timing early partnering discussions17:26: Structuring for efficient deals21:36: Planning commercialization from start25:22: Key early legal considerations30:00: Balancing fundraising and realism36:25: Optimism in the biotech industryInterested in being a sponsor of an episode of our podcast? <a href='https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&amp;utm_medium=podcast_description&amp;utm_source=podcast'>Discover how you can get involved here!</a> Stay updated by <a href='https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&amp;utm_medium=podcast_description&amp;utm_source=podcast'>subscribing to our newsletter</a>To dive deeper into the topic: <ul><li><a href='https://www.labiotech.eu/expert-advice/how-to-become-a-biotech-unicorn/'>How biotech startups become unicorns</a></li><li><a href='https://www.labiotech.eu/expert-advice/biotech-startup-funding/'>The ABC of biotech startup funding</a></li><li><a href='https://www.labiotech.eu/in-depth/biotech-lawsuits/'>Biotech’s legal storm: Why securities class action lawsuits are surging</a></li></ul>

<description>&lt;p&gt;Today, we welcome Janita Good, a Partner at &lt;a href='https://www.fieldfisher.com/en/sectors/life-sciences'&gt;Fieldfisher&lt;/a&gt; with nearly two decades of experience advising top organizations in pharmaceuticals, biotechnology, and medical devices. With a D.Phil. in Biochemistry from the University of Oxford, Janita brings a unique blend of scientific insight and legal expertise to her work on venture investments, joint ventures, partnerships, and M&amp;amp;A deals. She&amp;apos;s advised on landmark transactions, including funding rounds for Phynova and MedAnnex, and collaborations like Intelligent Ultrasound&amp;apos;s AI imaging partnerships.&lt;/p&gt;&lt;p&gt;In this episode, Janita shares practical guidance for biotech leaders on timing partnerships with larger pharma companies, planning for commercialization from the start, balancing optimistic fundraising with realistic deal projections, and avoiding common legal pitfalls in M&amp;amp;A. We&amp;apos;ll also look ahead to emerging trends in the sector and talk through the best way to structure a company for tax effective partnering and licensing.&lt;/p&gt;&lt;p&gt;01:29: Meet Janita Good&lt;/p&gt;&lt;p&gt;04:42: Fieldfisher&amp;apos;s life sciences focus&lt;/p&gt;&lt;p&gt;07:20: Fieldfisher’s differentiated approach&lt;/p&gt;&lt;p&gt;09:41: Timing early partnering discussions&lt;/p&gt;&lt;p&gt;17:26: Structuring for efficient deals&lt;/p&gt;&lt;p&gt;21:36: Planning commercialization from start&lt;/p&gt;&lt;p&gt;25:22: Key early legal considerations&lt;/p&gt;&lt;p&gt;30:00: Balancing fundraising and realism&lt;/p&gt;&lt;p&gt;36:25: Optimism in the biotech industry&lt;/p&gt;&lt;p&gt;Interested in being a sponsor of an episode of our podcast? &lt;a href='https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&amp;amp;utm_medium=podcast_description&amp;amp;utm_source=podcast'&gt;Discover how you can get involved here!&lt;/a&gt; &lt;/p&gt;&lt;p&gt;Stay updated by &lt;a href='https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&amp;amp;utm_medium=podcast_description&amp;amp;utm_source=podcast'&gt;subscribing to our newsletter&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;To dive deeper into the topic: &lt;/b&gt;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/expert-advice/how-to-become-a-biotech-unicorn/'&gt;How biotech startups become unicorns&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/expert-advice/biotech-startup-funding/'&gt;The ABC of biotech startup funding&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/in-depth/biotech-lawsuits/'&gt;Biotech’s legal storm: Why securities class action lawsuits are surging&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;</description>

Today, we welcome Janita Good, a Partner at Fieldfisher with nearly two decades of experience advising top organizations in pharmaceuticals, biotechnology, and medical devices. With a D.Phil. in Biochemistry from the University of Oxford, Janita brings a unique blend of scientific insight and legal expertise to her work on venture investments, joint ventures, partnerships, and M&amp;A deals. She's advised on landmark transactions, including funding rounds for Phynova and MedAnnex, and collabo...

How to optimize your biotech company for partnering, licensing, and business success

Today we’re joined by Sean MacDonald, CEO of <a href='https://www.kainovatx.com/en/'>Kainova Therapeutics</a>. With more than twenty years of biotech leadership and deep expertise in strategy and development, Sean is guiding the company through an exciting new chapter.We’ll dive into Kainova’s innovative GPCR-modulating platform, its promising pipeline, the science behind reversing tumor immunosuppression and targeting inflammation, and the reasons behind the recent rebrand from Domain Therapeutics to Kainova Therapeutics.We’ll also be taking a look at the broader oncology landscape—what’s hot, who’s investing big, and where the biggest opportunities and challenges lie.01:09 – Meet Sean Macdonald05:40 – Kainova&apos;s GPCR platform and therapeutic focus08:57 – The story and meaning behind the Kainova rebrand10:25 – Series B funding and pipeline programs16:43 – Exciting trends and innovations in oncology29:17 – Upcoming milestones and future plansInterested in being a sponsor of an episode of our podcast? <a href='https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&amp;utm_medium=podcast_description&amp;utm_source=podcast'>Discover how you can get involved here!</a> Stay updated by <a href='https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&amp;utm_medium=podcast_description&amp;utm_source=podcast'>subscribing to our newsletter</a>To dive deeper into the topic: <ul><li><a href='https://www.labiotech.eu/best-biotech/gpcr-therapies-eight-promising-biotechs-bolstering-rd/'>GPCR therapies: Eight promising biotechs hacking the cell signaling pathway</a></li><li><a href='https://podcast.labiotech.eu/1995493/episodes/18577193-building-a-smart-oncology-pipeline-with-cumulus-oncology'>Episode 182: Building a smart oncology pipeline with Cumulus Oncology</a></li><li><a href='https://podcast.labiotech.eu/1995493/episodes/12272139-beyond-biotech-podcast-34-eclinical-solutions-gpcr-therapeutics-orbsen-therapeutics'>Episode 34: eClinical Solutions, GPCR Therapeutics, Orbsen Therapeutics</a></li></ul>

<description>&lt;p&gt;Today we’re joined by &lt;b&gt;Sean MacDonald&lt;/b&gt;, CEO of &lt;a href='https://www.kainovatx.com/en/'&gt;&lt;b&gt;Kainova Therapeutics&lt;/b&gt;&lt;/a&gt;. With more than twenty years of biotech leadership and deep expertise in strategy and development, Sean is guiding the company through an exciting new chapter.&lt;/p&gt;&lt;p&gt;We’ll dive into Kainova’s innovative GPCR-modulating platform, its promising pipeline, the science behind reversing tumor immunosuppression and targeting inflammation, and the reasons behind the recent rebrand from Domain Therapeutics to Kainova Therapeutics.&lt;/p&gt;&lt;p&gt;We’ll also be taking a look at the broader oncology landscape—what’s hot, who’s investing big, and where the biggest opportunities and challenges lie.&lt;/p&gt;&lt;p&gt;01:09 – Meet Sean Macdonald&lt;/p&gt;&lt;p&gt;05:40 – Kainova&amp;apos;s GPCR platform and therapeutic focus&lt;/p&gt;&lt;p&gt;08:57 – The story and meaning behind the Kainova rebrand&lt;/p&gt;&lt;p&gt;10:25 – Series B funding and pipeline programs&lt;/p&gt;&lt;p&gt;16:43 – Exciting trends and innovations in oncology&lt;/p&gt;&lt;p&gt;29:17 – Upcoming milestones and future plans&lt;/p&gt;&lt;p&gt;Interested in being a sponsor of an episode of our podcast? &lt;a href='https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&amp;amp;utm_medium=podcast_description&amp;amp;utm_source=podcast'&gt;Discover how you can get involved here!&lt;/a&gt; &lt;/p&gt;&lt;p&gt;Stay updated by &lt;a href='https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&amp;amp;utm_medium=podcast_description&amp;amp;utm_source=podcast'&gt;subscribing to our newsletter&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;To dive deeper into the topic: &lt;/b&gt;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/best-biotech/gpcr-therapies-eight-promising-biotechs-bolstering-rd/'&gt;GPCR therapies: Eight promising biotechs hacking the cell signaling pathway&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href='https://podcast.labiotech.eu/1995493/episodes/18577193-building-a-smart-oncology-pipeline-with-cumulus-oncology'&gt;Episode 182: Building a smart oncology pipeline with Cumulus Oncology&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href='https://podcast.labiotech.eu/1995493/episodes/12272139-beyond-biotech-podcast-34-eclinical-solutions-gpcr-therapeutics-orbsen-therapeutics'&gt;Episode 34: eClinical Solutions, GPCR Therapeutics, Orbsen Therapeutics&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;</description>

Today we’re joined by Sean MacDonald, CEO of Kainova Therapeutics. With more than twenty years of biotech leadership and deep expertise in strategy and development, Sean is guiding the company through an exciting new chapter. We’ll dive into Kainova’s innovative GPCR-modulating platform, its promising pipeline, the science behind reversing tumor immunosuppression and targeting inflammation, and the reasons behind the recent rebrand from Domain Therapeutics to Kainova Therapeutics. We’ll also ...

Reversing tumor immunosuppression with next-gen GPCR modulation

Our guest is Sergey Jakimov, the Founding and Managing Partner of <a href='https://longevc.com'>LongeVC</a>, a venture capital firm dedicated to backing early-stage biotech and longevity startups. A serial entrepreneur, Sergey has co-founded ventures like Longenesis, a medical tech startup unlocking biomedical data for drug discovery, and the Longevity Science Foundation, a non-profit advancing healthy human lifespan. He’s been named to Forbes Latvia&apos;s 30 Under 30 in technology and healthcare, and via LongeVC, he invests in innovation in areas including therapeutics, diagnostics, and personalized medicine.In this episode, Sergey warns about the rising danger of misinformation disguised as health advice—where influencers and hype outpace evidence-based science. I hope you enjoy our discussion as we unpack this public health challenge and explore solutions for a more credible biotech landscape.<ul><li>01:22           Meet Sergey Jakimov</li><li>06:14           Developing a longevity focus</li><li>10:47           A typical day at LongeVC</li><li>13:26           The LongeVC portfolio</li><li>17:28           Misinformation as health crisis</li><li>26:04           The harm of bad advice</li><li>33:16           The impact on biotech industry funding</li><li>36:18           Strategies for addressing misinformation</li><li>42:17           Optimism about trends in longevity</li></ul>Interested in being a sponsor of an episode of our podcast? <a href='https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&amp;utm_medium=podcast_description&amp;utm_source=podcast'>Discover how you can get involved here!</a> Stay updated by <a href='https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&amp;utm_medium=podcast_description&amp;utm_source=podcast'>subscribing to our newsletter</a>To dive deeper into the topic: <ul><li><a href='https://www.labiotech.eu/best-biotech/anti-aging-biotech-companies/'>13 anti-aging startups on a mission to extend lives</a></li><li><a href='https://www.labiotech.eu/trends-news/cellular-reprogramming/'>Turning back time with cellular reprogramming: Shift raises $16 million in seed funding</a></li><li><a href='https://www.labiotech.eu/trends-news/european-biotech-vc/'>Are European biotech VCs under pressure to scale? Time to get pragmatic</a> </li></ul>

<description>&lt;p&gt;Our guest is Sergey Jakimov, the Founding and Managing Partner of &lt;a href='https://longevc.com'&gt;LongeVC&lt;/a&gt;, a venture capital firm dedicated to backing early-stage biotech and longevity startups. A serial entrepreneur, Sergey has co-founded ventures like Longenesis, a medical tech startup unlocking biomedical data for drug discovery, and the Longevity Science Foundation, a non-profit advancing healthy human lifespan. He’s been named to Forbes Latvia&amp;apos;s 30 Under 30 in technology and healthcare, and via LongeVC, he invests in innovation in areas including therapeutics, diagnostics, and personalized medicine.&lt;/p&gt;&lt;p&gt;In this episode, Sergey warns about the rising danger of misinformation disguised as health advice—where influencers and hype outpace evidence-based science. I hope you enjoy our discussion as we unpack this public health challenge and explore solutions for a more credible biotech landscape.&lt;/p&gt;&lt;ul&gt;&lt;li&gt;01:22           Meet Sergey Jakimov&lt;/li&gt;&lt;li&gt;06:14           Developing a longevity focus&lt;/li&gt;&lt;li&gt;10:47           A typical day at LongeVC&lt;/li&gt;&lt;li&gt;13:26           The LongeVC portfolio&lt;/li&gt;&lt;li&gt;17:28           Misinformation as health crisis&lt;/li&gt;&lt;li&gt;26:04           The harm of bad advice&lt;/li&gt;&lt;li&gt;33:16           The impact on biotech industry funding&lt;/li&gt;&lt;li&gt;36:18           Strategies for addressing misinformation&lt;/li&gt;&lt;li&gt;42:17           Optimism about trends in longevity&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;Interested in being a sponsor of an episode of our podcast? &lt;a href='https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&amp;amp;utm_medium=podcast_description&amp;amp;utm_source=podcast'&gt;Discover how you can get involved here!&lt;/a&gt; &lt;/p&gt;&lt;p&gt;Stay updated by &lt;a href='https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&amp;amp;utm_medium=podcast_description&amp;amp;utm_source=podcast'&gt;subscribing to our newsletter&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;To dive deeper into the topic: &lt;/b&gt;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/best-biotech/anti-aging-biotech-companies/'&gt;13 anti-aging startups on a mission to extend lives&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/trends-news/cellular-reprogramming/'&gt;Turning back time with cellular reprogramming: Shift raises $16 million in seed funding&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/trends-news/european-biotech-vc/'&gt;Are European biotech VCs under pressure to scale? Time to get pragmatic&lt;/a&gt; &lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;br/&gt;&lt;/p&gt;</description>

Our guest is Sergey Jakimov, the Founding and Managing Partner of LongeVC, a venture capital firm dedicated to backing early-stage biotech and longevity startups. A serial entrepreneur, Sergey has co-founded ventures like Longenesis, a medical tech startup unlocking biomedical data for drug discovery, and the Longevity Science Foundation, a non-profit advancing healthy human lifespan. He’s been named to Forbes Latvia's 30 Under 30 in technology and healthcare, and via LongeVC, he invests in i...

Misinformation is a public health crisis - here's how to fix it

Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.

Beyond Biotech - the podcast from Labiotech

Details

Recent Episodes